{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:29:13Z","timestamp":1787682553084,"version":"build-2784847793"},"reference-count":36,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>First\u2010 and second\u2010 generation new treatments are being evaluated to provide a cure for hepatitis B. The life cycle of HBV includes several well\u2010 categorized steps that are targets for new treatments. A cure remains a major challenge even if it is measured by HBsAg seroclearance alone. The notion of a functional cure of hepatitis B has been accepted, while a partial functional cure has been more tentatively defined as a decline in HBsAg concentrations to lower levels after finite treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>More profound suppression of hepatitis B replication through the addition of capsid inhibitors with nucleoside analogues could improve patient prognosis and a sustained treatment response. Several strategies are being evaluated to achieve a cure: (a) deepening inhibition of HBV replication or (b) a reduction in HBsAg presentation for HBsAg seroclearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fortunately, there are signs of important progress in the treatment of hepatitis B including improved on\u2010 treatment reductions or seroclearance of HBsAg in phase 2 studies that was not achieved with chain terminators and inhibitors of initiation of DNA synthesis. Progress in immunomodulatory therapy has lagged behind that of antiviral therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Increasing the multilayered impaired and dysfunctional immune response in hepatitis B is perhaps more likely and feasible after a reduction in host antigen burden. Other potential experimental strategies include CRISPR\u2010 Cas9 genome\u2010 editing nucleases to specifically target and cleave cccDNA or novel monoclonal antibodies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.14837","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T05:38:49Z","timestamp":1624340329000},"page":"24-29","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatitis B cure: How and when"],"prefix":"10.1111","volume":"41","author":[{"given":"Geoffrey","family":"Dusheiko","sequence":"first","affiliation":[{"name":"University College London School of Medicine Kings College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.018"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","unstructured":"Van BuurenN.Delineating HBV transcripts from integrated viral DNA using target enrichment and long\u2010read sequencing. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)32128-0"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908365106"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169648"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.10.018"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.003"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305517"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.014"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.10.027"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.015"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243462"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30417"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13751"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.012"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","unstructured":"Garcia\u2010LopezM.Serum and intrahepatic HBV markers and HBV specific CD8 T cell responses after nucleoside analogue therapy discontinuation in HBeAg negative chronic hepatitis B patients. Paper presented at: EASL Digital conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30573-0"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","unstructured":"Van BommelF.Response to discontinuation of long\u2010term nucleos(tide analogue treatment in HBeAg negative patients: results of the Stop\u2010NUC trial. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30755-8"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","unstructured":"HallS.HBV STOP: A prospective study of nucleot(s)ide analogue (NA) discontinuation in non\u2010cirrhotic HBeAg\u2010negative CHB patients: Interim analysis at Week 48 demonstrates profound reductions of HBsAg associated with ALT flare. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30674-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","unstructured":"GaneE.Short\u2010term treatment with RNA interference therapy JNJ\u20103989 results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30597-3"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","unstructured":"YuenMF.HBsAg inhibition with ISIS 505358 in CHB patients on stable NA regimen and in NA\u2010naive CHB patients: Phase 2a randomized double\u2010blind placebo\u2010controlled study. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30646-2"},{"key":"e_1_2_12_23_1","article-title":"Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro","volume":"104853","author":"Boulon R","year":"2020","journal-title":"Antiviral Res"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","unstructured":"BazinetM.Analysis of HBsAg levels HBsAg isoforms HBsAg immune complexes HBV pregenomic RNA and HBcrAg dynamics during and after NAP\u2010based combination therapy in the REP 301\u2010LTF and REP 401 studies.2020.","DOI":"10.1016\/S0168-8278(20)30793-5"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","unstructured":"FitzgeraldM.Structural requirements for S\u2010antigen transport\u2010inhibiting oligonucleotide polymer inhibition of hepatitis B surface antigen secretion. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)32194-2"},{"key":"e_1_2_12_27_1","first-page":"58A","article-title":"Safety and efficay of 10 mg bulevertide (myrcludex B) in combination with PEG interferon alpha2a or tenofovir in patients with chronic HBV HDV coinfection: week 24 interim results of the MYR203 extension study","volume":"70","author":"Wedemeyer H","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01463-20"},{"key":"e_1_2_12_29_1","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature\u2010mutation in treated chronic hepatitis B patients","author":"Huang Q","year":"2020","journal-title":"Hepatology"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02439-19"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30346-2"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","unstructured":"JanssenH.Efficacy and safety results of the Phase 2 JNJ\u201056136379 JADE study in patients with CHB: Interim Week 24 data. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30773-X"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","unstructured":"FungS.Antiviral activity and safety of the hepatitis B core inhibitor ABI\u2010H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg\u2010negative chronic hepatitis B infection. Paper presented at: EASL Digital conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30649-8"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","unstructured":"YuenMF.Antiviral activity and safety of the hepatitis B core inhibitor ABI\u2010H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg+ CHB infection in a long\u2010term extension study. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30790-X"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","unstructured":"GaneE.Efficacy and safety of 24 weeks treatment with oral TLR8 agonist selgantolimod in virally\u2010suppressed adult patients with CHB: A Phase 2 study. Paper presented at: EASL Digital Conference 2020; Geneva.","DOI":"10.1016\/S0168-8278(20)30650-4"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.032"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0196-9"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T08:33:20Z","timestamp":1693298000000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14837"}},"subtitle":[],"editor":[{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":36,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/liv.14837"],"URL":"https:\/\/doi.org\/10.1111\/liv.14837","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2021-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}